Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.
Rodríguez
Miguel
M
Enrique
Ernesto
E
Castello
Jose V
JV
de Mateo
Jose A
JA
Roca
Bernardino
B
Malek
Tamim
T
D000082:Acetaminophen / Q000009:adverse effects; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000068579:Celecoxib; D051545:Cyclooxygenase 1; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects; D007783:Lactones / Q000009:adverse effects; D008297:Male; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones; D014581:Urticaria / Q000139:chemically induced / Q000188:drug therapy
D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000082:Acetaminophen; D051545:Cyclooxygenase 1; C496511:PTGS1 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib